Use of temozolomide in aggressive pituitary tumors: Case report

Neurosurgery

Volumn 64, Issue 4, 2009, Pages

  Mohammed, Safraz ^a   Kovacs, Kalman ^a   Mason, Warren ^b   Smyth, Harley ^c   Cusimano, Michael D ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c Trillium Health Centre   (Canada)

Author keywords

Chemotherapy; Crooke's cell adenoma; Pituitary adenoma; Temozolomide; Treatment

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; PROLACTIN; SOMATOSTATIN DERIVATIVE; TEMOZOLOMIDE;

ADRENALECTOMY; ADULT; ARTICLE; BRAIN BIOPSY; BRAIN HEMORRHAGE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CORTICOTROPIN BLOOD LEVEL; CRANIOTOMY; DEEP VEIN THROMBOSIS; ENDOCRINOLOGY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HEADACHE; HEMIANOPIA; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; MALE; MIXED INFECTION; MULTIPLE CYCLE TREATMENT; NELSON SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOPLEGIA; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PTOSIS; RADIATION DOSE; STEREOTACTIC TREATMENT; SURGICAL TECHNIQUE; THYROID FUNCTION; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TUMOR VOLUME;

ADENOMA; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; CUSHING SYNDROME; DACARBAZINE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS;

EID: 67649839955     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000339115.12803.4E     Document Type: Article

References (16)

1. Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Pepin SE, Simmons NE: Pituitary carcinomas respond to temozolomide. Neuro-Oncol 6:374, 2004.
2. George DH, Scheithauer BW, Kovacs K, Horvath E, Young WF Jr, Lloyd RV, Meyer FB: Crooke's cell adenoma of the pituitary: An aggressive variant of corticotroph adenoma. Am J Surg Pathol 27:1330-1336, 2003.
3. Kaltsas GA, Grossman AB: Malignant pituitary tumours. Pituitary 1:69-81, 1998.
4. Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM: The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 83:4233-4238, 1998.
5. Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE: Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum Pathol 38:185-189, 2007.
6. Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC: MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115:261-262, 2008.
7. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP: Temozolomide: A novel treatment for pituitary carcinoma. Lancet Oncol 7:518-520, 2006.
8. Mortini P, Barzaghi R, Losa M, Boari N, Giovanelli M: Surgical treatment of giant pituitary adenomas: Strategies and results in a series of 95 consecutive patients. Neurosurgery 60:993-1004, 2007.
9. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C: Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35-61, 1997.
10. Park P, Chandler WF, Barkan AL, Orrego JJ, Cowan JA, Griffith KA, Tsien C: The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 55:100-107, 2004.
11. Payne MJ, Pratap SE, Middleton MR: Temozolomide in the treatment of solid tumours: Current results and rationale for dosing/scheduling. Crit Rev Oncol Hematol 53:241-252, 2005.
12. Ragel BT, Couldwell WT: Pituitary carcinoma: A review of the literature. Neurosurg Focus 16:E7, 2004.
13. Scheithauer BW, Kovacs KT, Laws ER Jr, Randall RV: Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 65:733-744, 1986.
14. Stupp R, Gander M, Leyvraz S, Newlands E: Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2:552-560, 2001.
15. Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E, Kovacs K: Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 65:552-553, 2006.
16. Zhu Y Shahinian H, Hakimian B, Bonert V, Lim S, Heaney A: Temodar: Novel treatment for pituitary carcinoma. Abstr US Endocr Soc 138:43-45, 2004.